Deep transcranial magnetic stimulation add-on for treatment of negative symptoms and cognitive deficits of schizophrenia: a feasibility study

被引:63
|
作者
Levkovitz, Yechiel [1 ,2 ,3 ]
Rabany, Liron [1 ,2 ,4 ]
Harel, Eiran Vadim [1 ,2 ]
Zangen, Abraham [5 ]
机构
[1] Shalvata Mental Hlth Care Ctr, Emot Cognit Res Ctr, Hod Hasharon, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Tel Aviv Univ, Gordon Fac Social Sci, IL-69978 Tel Aviv, Israel
[5] Weitzman Inst Sci, Dept Neurobiol, Rehovot, Israel
来源
关键词
Cognition; negative symptoms; schizophrenia; transcranial magnetic stimulation; BRAIN; RTMS;
D O I
10.1017/S1461145711000642
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Treatment for negative symptoms and cognitive deficits, core elements of schizophrenia, remains inadequate. Stimulation of the prefrontal cortex via transcranial magnetic stimulation (TMS) yields only moderate results, possibly due to limited stimulation depth. Deep-TMS enables deeper and wider stimulation than before. This preliminary study is the first to examine deep-TMS as a possible add-on treatment for negative symptoms and cognitive deficits of schizophrenia. The effect of 20 daily deep-TMS sessions (20 Hz, 120% motor threshold) over the prefrontal cortex of 15 patients indicated improvement in cognition and negative symptoms that was maintained at 2-wk post-treatment follow-up.
引用
收藏
页码:991 / 996
页数:6
相关论文
共 50 条
  • [31] Accelerated Repetitive Transcranial Magnetic Stimulation in the Treatment of Negative Symptoms of Schizophrenia An Open-Label Study
    Sverak, Tomas
    Mayerova, Michaela
    Obdrzalkova, Marie
    Ustohal, Libor
    JOURNAL OF ECT, 2022, 38 (02) : E24 - E25
  • [32] Repetitive transcranial magnetic stimulation as new technique for treatment of negative symptoms of schizophrenia - Reply
    Stahl, Stephen
    Buckley, Peter F.
    ACTA PSYCHIATRICA SCANDINAVICA, 2008, 117 (01) : 79 - 79
  • [33] Transcranial random noise stimulation for the treatment of negative symptoms in schizophrenia
    Palm, Ulrich
    Hasan, Alkomiet
    Keeser, Daniel
    Falkai, Peter
    Padberg, Frank
    SCHIZOPHRENIA RESEARCH, 2013, 146 (1-3) : 372 - 373
  • [34] Use of Transcranial Direct Stimulation in the Treatment of Negative Symptoms of Schizophrenia
    Pontillo, Maria
    Costanzo, Floriana
    Menghini, Deny
    Averna, Roberto
    Santonastaso, Ornella
    Tata, Maria Cristina
    Vicari, Stefano
    CLINICAL EEG AND NEUROSCIENCE, 2018, 49 (01) : 18 - 26
  • [35] Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study
    Mogg, Andrew
    Purvis, Rick
    Eranti, Savitha
    Contell, Faith
    Taylor, John P.
    Nicholson, Tiniothy
    Brown, Richard G.
    McLoughlin, Declan M.
    SCHIZOPHRENIA RESEARCH, 2007, 93 (1-3) : 221 - 228
  • [36] Vortioxetine as add-on strategy for treating negative symptoms in schizophrenia
    Esteves-Sousa, D.
    Gago, J.
    Gomes-Pereira, S.
    Neto, D.
    Facucho-Oliveira, J.
    Albuquerque, M.
    Mendonca, L.
    EUROPEAN PSYCHIATRY, 2019, 56 : S256 - S256
  • [37] Reboxetine add-on to clozapine in treatment of negative symptoms of schizophrenia: a preliminary open-label study
    Quattrone, D.
    Bruno, A.
    Mico, U.
    Pandolfo, G.
    Scimeca, G.
    Muscatello, M. R.
    Zoccali, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S469 - S469
  • [38] Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia
    Goff, Donald C.
    WORLD PSYCHIATRY, 2013, 12 (02) : 99 - 107
  • [39] REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (RTMS) FOR DEPRESSION AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
    Maslenikov, Nikita V.
    Tsukarzi, Eduard E.
    Mosolov, Sergey N.
    ISRAEL JOURNAL OF PSYCHIATRY AND RELATED SCIENCES, 2012, 49 (01): : 59 - 59
  • [40] Intensive repetitive transcranial magnetic stimulation for negative symptoms in patients with schizophrenia
    Ustohal, L.
    Sverak, T.
    Mayerova, M.
    Obdrzalkova, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S602 - S602